SHUTTLE PHARMACEUTICALS HOLDINGS, INC.: 10-Q filed 2023-11-13
What SHUTTLE PHARMACEUTICALS HOLDINGS, INC. reported in its quarterly report filed 2023-11-13 (fiscal Q3 2023): 31 published measures, 91 facts as tagged in accession 0001493152-23-040531.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2023-11-13
- Fiscal period
- fiscal Q3 2023
- Accession
- 0001493152-23-040531 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SHUTTLE PHARMACEUTICALS HOLDINGS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 7,375,818 | USD | |
| At 2022-12-31 | 8,653,545 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 1,766,069 | USD | |
| At 2022-12-31 | 975,676 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 5,609,749 | USD | |
| At 2023-06-30 | 6,935,610 | USD | |
| At 2023-03-31 | 6,906,468 | USD | |
| At 2022-12-31 | 7,677,869 | USD | |
| At 2022-09-30 | 8,404,875 | USD | |
| At 2022-06-30 | -2,306,073 | USD | |
| At 2022-03-31 | -1,849,563 | USD | |
| At 2021-12-31 | -1,628,132 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 3,885,997 | USD | |
| At 2022-12-31 | 8,417,203 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -1,792,754 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -4,952,223 | USD | 273 |
| 2023-04-01 to 2023-06-30 | -2,184,372 | USD | 91 |
| 2023-01-01 to 2023-03-31 | -975,097 | USD | 90 |
| 2022-07-01 to 2022-09-30 | -998,425 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -2,277,539 | USD | 273 |
| 2022-04-01 to 2022-06-30 | -597,275 | USD | 91 |
| 2022-01-01 to 2022-03-31 | -681,839 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -4,518,973 | USD | 273 |
| 2022-01-01 to 2022-09-30 | -2,030,587 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 19,046 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 2,904,527 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 10,646,228 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -2,916,760 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | -13,847,112 | USD | |
| At 2022-12-31 | -8,894,889 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 15,744,210 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 14,554,878 | shares | 273 |
| 2022-07-01 to 2022-09-30 | 10,164,979 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 9,723,510 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -0.11 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -0.34 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | -0.1 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -0.23 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -0.11 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -0.34 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | -0.1 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -0.23 | USD/shares | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 26,810 | USD | |
| At 2022-12-31 | 12,592 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 95,438 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 356,733 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -1,599,146 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -4,609,558 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -821,468 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -1,813,490 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 6,995,608 | USD | |
| At 2022-12-31 | 8,578,351 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 810,437 | USD | |
| At 2022-12-31 | 975,676 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 1,599,146 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 4,609,558 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 821,468 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 1,813,490 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 1,140,307 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 3,084,488 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 669,038 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 1,048,821 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 15,999,125 | shares | |
| At 2022-12-31 | 13,603,129 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 19,456,701 | USD | |
| At 2022-12-31 | 16,572,622 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 353,400 | USD | |
| At 2022-12-31 | 56,122 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-12-31 | 6,480 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -1,775,254 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -4,952,223 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -998,425 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -2,277,539 | USD | 273 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -1,792,754 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -4,952,223 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -1,017,898 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -2,348,548 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 170,423 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 452,342 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 81,864 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 104,711 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 4,828 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 4,484 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -193,608 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -342,665 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -176,957 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -464,049 | USD | 273 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 102,373 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 17,489 | USD | 273 |
Operating lease payments
Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 73,884 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 56,617 | USD | 273 |
Inspect the source
- Entity
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. / CIK 0001757499
- Captured
- 2026-09-21T17:26:13.691Z
- SEC response SHA-256
f49398c3e7cd3b164788dc7de69572106cc3dd5ae8796315796502dfdc662883
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001757499.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))